Financial Architects (New Jersey)’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Financial Architects (New Jersey)’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-525	Closed	-$9K	–	1568
2018 Q3	$9K	Hold	525	–	–	﹤0.01%	1151
2018 Q2	$7K	Hold	525	–	–	﹤0.01%	1084
2018 Q1	$5K	Hold	525	–	–	﹤0.01%	1247
2017 Q4	$2K	Hold	525	–	–	﹤0.01%	1431
2017 Q3	$1K	Hold	525	–	–	﹤0.01%	1467
2017 Q2	$1K	Hold	525	–	–	﹤0.01%	1497
2017 Q1	$1K	Hold	525	–	–	﹤0.01%	1548
2016 Q4	$1K	Hold	525	–	–	﹤0.01%	1374
2016 Q3	$2K	Hold	525	–	–	﹤0.01%	1374
2016 Q2	$2K	Buy	+525	New	+$1.92K	﹤0.01%	1367

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Financial Architects (New Jersey)'s ECYT Position: Q4 2018 in Review

Financial Architects (New Jersey) sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 525 shares — an estimated $9K sold.

Financial Architects (New Jersey) first reported a position in ECYT in Q2 2016 and held it in 10 quarters. The position peaked at $9K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Financial Architects (New Jersey) reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Financial Architects (New Jersey) sold 525 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $9K.
Financial Architects (New Jersey) first reported a position in Endocyte, Inc. Common Stock in Q2 2016 and held it in 10 quarters.
Financial Architects (New Jersey)'s Endocyte, Inc. Common Stock position peaked at $9K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2018, filed 1 Feb 2019.